Markus Moehler is and has been principal investigator on numerous national and international clinical studies. For the German AIO and the EORTC, he has been organizing many randomized phase II-III trials (many IIT studies) on GI cancers and has been involved in many novel agents including irinotecan, oxaliplatin, cetuximab, bevacizumab, trastuzumab, lapatinib, erlotinib, sorafenib and sunitinib
After his studies at Heidelberg University with Internships at Basel University, Switzerland, and at Albert Einstein College of Yeshiva University, New York (USMLE 1993), he made his doctoral dissertation supervised by Nobel-Prize laureate Prof. zur Hausen and a 2-year Research Post-Doc at the German Cancer Research Center, Division of Tumor Biochemistry and Applied Tumor Virology.
Since 1999 he is working at Mainz Medical University Hospital, Dept. of Gastroenterology, Hepatology, (Prof. Dr. P.R. Galle), and received his Degree of Internal Medicine (2003) and his ESMO Certificate (2003).
In February 2005 he became Gastroenterologist, as well as Consultant for Gastroenterology and GI Oncology.
Apart from many German associations (DGVS, DGHO, gene therapy group etc), he is active member of EORTC GI board (organized the EORTC GI autumn meeting 2007 in Mainz), American Society of Clinical Oncology (ASCO), European Society of Medical Oncology (ESMO) and German Arbeitsgemeinschaft Internistische Onkologie (AIO). Here he is active in the AIO colorectal cancer group and team leader of the AIO upper GI group (esophagus/gastric cancer).
For the German DGVS, he leads together with M. Ebert the steering committee of gastric cancer (http://www.dgvs.de/329.php).
Presently he is responsible for the organisation of the new national-wide guideline for gastric cancer in Germany.